Figure 2.

Depiction of reported toxicities in CAR‐T cell therapy. “On target, off tumor” toxicity potentially leading to profound fratricide T cells and hyperimmune activation, for example, the cytokine release syndrome (CRS), while cross‐reactivity leads to B‐cell remission relapses and T‐lineage neoplasms. Other serious side effects include abnormalities in the central nervous system (CNS), arterial hypotension, sickle cell anemia, and sometimes organ damage.